PRISM BioLab and Lilly Enter into a Drug Discovery Collaboration on a Protein-Protein Interaction Target
Collaboration focused on discovering oral inhibitors of protein-protein interaction (PPI) targets by leveraging PRISM BioLab's proprietary PepMetics® technology. PRISM BioLab receives upfront payments and up to $660 million in total milestones, plus...